MacroGenics (MGNX) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 99.4% versus a loss of 31.6%. Over five years, MGNX leads with a -82.0% price change compared with -83.1% for PYXS. Pyxis Oncology is the larger company by market cap ($241.9 million vs $233.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | PYXS |
|---|---|---|
| Share price | $3.67 | $2.03 |
| Market cap | $233.78M | $241.90M |
| 1-day change | +3.38% | +1.76% |
| YTD return | +120.50% | +73.04% |
| 1-year return | +99.44% | -31.62% |
| 5-year return | -82.02% | -83.09% |
| EPS (TTM) | $-1.70 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $5.55 |
| 52-week low | $1.29 | $1.03 |
| Distance from 52-week high | -27.76% | -63.51% |
| Analyst consensus | buy | none |
| Avg. price target upside | +117.98% | +328.15% |
| Average volume | 622.92K | 1.26M |
| Shares outstanding | 63.70M | 119.46M |
| Employees | 293 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed PYXS by 131.1 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
MGNX vs PYXS FAQ
Which is bigger, MacroGenics or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $241.90M compared with $233.78M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or PYXS?
MGNX returned +99.44% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.